CD312 CAR-T cells

CD312 CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target CD312 (also known as EMR2 or ADGRE2), a member of the adhesion G protein-coupled receptor family. CD312 is highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSCs) but is notably absent on normal hematopoietic stem and progenitor cells (HSPCs), potentially offering a wider therapeutic window than other AML targets. While early research utilized single-target CD312 CAR-T cells, current development focuses on a "split" or "AND-gated" dual CAR-T design. This approach requires the simultaneous recognition of both CD312 and a second antigen, such as TIM-3 (Hepatitis A virus cellular receptor 2), to trigger full T-cell activation. This dual-targeting strategy is intended to eradicate LSCs and prevent disease relapse while minimizing off-target toxicity against normal myeloid tissues.

Other names

anti-CD312 CAR-T cellsanti-CD-312 CAR-T cellsanti-CD 312 CAR-T cellsEMR2 CAR-T cellsEMR-2 CAR-T cellsEMR 2 CAR-T cellsADGRE2 CAR-T cellsADGRE-2 CAR-T cellsADGRE 2 CAR-T cellsCD312-TIM-3 split CAR-T cellsCD-312-TIM-3 split CAR-T cellsCD 312-TIM-3 split CAR-T cells